Țară: Cipru
Limbă: greacă
Sursă: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
OMEPRAZOLE
BIAL-PORTELA & CA, SA (0000003750) A AV. DA SIDERURGIA NACIONAL, S. MAMEDE DO CORONADO, 4745-457
A02BC01
OMEPRAZOLE
20MG
GASTRO-RESISTANT CAPSULE, HARD
OMEPRAZOLE (0073590586) 20MG
ORAL USE
Εθνική Διαδικασία
OMEPRAZOLE
Νομικό καθεστώς: Χωρίς Ιατρική Συνταγή Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 14 CAPS IN BLISTER(S) (200036201) 14 CAPSULE - Εγκεκριμένο - Χωρίς Ιατρική Συνταγή; PACK WITH 28 CAPS IN BLISTER(S) (200036202) 28 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται
PACKAGE LEAFLET: INFORMATION FOR THE USER OMPRANYT, 20 MG, TABLETS OMEPRAZOLE OMPRANYT, 20 MG, CAPSULES OMEPRAZOLE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have further questions, ask your doctor or your pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What OMPRANYT is and what it is used for 2. Before you take OMPRANYT 3. How to take OMPRANYT 4. Possible side effects 5 How to store OMPRANYT 6. Further information 1. WHAT OMPRANYT IS AND WHAT IT IS USED FOR Pharmacotherapeutic group: Proton Pump Inhibitors. The active substance is omeprazole, a drug that reduces gastric acid secretion. OMPRANYT is indicated for: Treatment of duodenal ulcer and benign gastric ulcer, including those which complicate the treatments with nonsteroidal anti-inflammatory drugs (NSAIDs). Prophylactic treatment of duodenal ulcer, benign gastric ulcer and/or gastroduodenal erosions resulting from nonsteroidal anti-inflammatory drugs (NSAIDs) in patients at risk (elderly and/ or with history of gastroduodenal erosions), requiring continuous treatment with NSAIDs. Treatment of gastroesophageal reflux. Treatment of Zollinger-Ellison syndrome, a disease where the acid gastric secretion is highly increased. Treatment of gastric and duodenal ulcer associated to _Helicobacter pylori _(a bacteria which is associated to the establishment of the ulcer). 2. BEFORE YOU TAKE OMPRANYT DO NOT TAKE OMPRANYT: If you are allergic (hypersensitive) to omeprazole or to any of the other ingredients of OMPRANYT. In case of persistence of symptoms it should be excluded the hypothesis of malignant disease, as treatment with omeprazole may relief the symptoms and delay its diagnosis. TAKE SPEC Citiți documentul complet
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT OMPRANYT, 20 mg, capsules. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each capsule contains: Omeprazole, 20 mg. For full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM: Gastro-resistant capsule, hard. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS: Treatment of duodenal ulcer and benign gastric ulcer, including those which complicate the treatment with nonsteroidal anti-inflammatory drugs (NSAIDs). Prophylactic treatment of duodenal ulcer, benign gastric ulcer and/or gastroduodenal erosions resulting from nonsteroidal anti-inflammatory drugs (NSAIDs) in patients at risk (elderly and/ or history of gastroduodenal erosions), requiring continuous treatment with NSAIDs. Treatment of gastroesophageal reflux. Omeprazole is indicated in the treatment of reflux esophagitis, of severe symptoms of non-inflammatory reflux, and of mild symptoms that do not respond to the conventional treatment. Treatment of Zollinger-Ellison syndrome. Treatment of gastric and duodenal ulcer associated to _Helicobacter pylori _either as dual therapy (in combination with amoxicillin or clarithromycin) or triple therapy (combined treatment, with two anti- infective agents simultaneously) whose eradication rate is substantially higher with minimum duration of therapy. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION: Omeprazole will be administered orally, preferably in the morning, taking the whole capsule with some liquid. Patients having difficulty to swallow the capsule can open it and either swallow the capsule’s content or mix it with mildly acidic liquid (e.g. juice, yoghurt or sour milk). Suspension is recommended to be taken within 30 minutes. Patients can swallow directly the content’s capsule but never masticate or crash the granules. _DUODENAL ULCER: _Recommended posology in patients with active peptic ulcer is 20 mg once daily. Symptom resolution is rapid and in most patients healing occurs within 2 weeks. In patients were ulcer cicatrisation is i Citiți documentul complet